Premium
Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells
Author(s) -
Brechbuhl Heather M.,
VinodPaul Kiran,
Gillen Austin E.,
Kopin Etana G.,
Gibney Kari,
Elias Anthony D.,
Hayashi Masanori,
Sartorius Carol A.,
Kabos Peter
Publication year - 2020
Publication title -
molecular carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 97
eISSN - 1098-2744
pISSN - 0899-1987
DOI - 10.1002/mc.23242
Subject(s) - circulating tumor cell , biology , peripheral blood mononuclear cell , breast cancer , transcriptome , cancer , population , cancer research , immune system , epithelial–mesenchymal transition , cancer cell , intravasation , immunology , metastasis , medicine , gene , gene expression , biochemistry , genetics , environmental health , in vitro
Abstract For solid tumors, extravasation of cancer cells and their survival in circulation represents a critical stage of the metastatic process that lacks complete understanding. Gaining insight into interactions between circulating tumor cells (CTCs) and other peripheral blood mononuclear cells (PBMCs) may provide valuable prognostic information. The purpose of this study was to use single‐cell RNA‐sequencing (scRNA‐seq) of liquid biopsies from breast cancer patients to begin defining intravascular interactions. We captured CTCs from the peripheral blood of breast cancer patients using size‐exclusion membranes followed by scRNA‐seq of enriched CTCs and carry‐over PBMCs. Transcriptome analysis identified two populations of CTCs: one enriched for transcripts indicative of estrogen responsiveness and increased proliferation and another enriched for transcripts characteristic of reduced proliferation and epithelial–mesenchymal transition (EMT). We applied interactome and pathway analysis to determine interactions between CTCs and other captured cells. Our analysis predicted for enhanced immune evasion in the CTC population with EMT characteristics. In addition, PD‐1/PD‐L1 pathway activation and T cell exhaustion were predicted in T cells isolated from breast cancer patients compared with normal T cells. We conclude that scRNA‐seq of breast cancer CTCs generally stratifies them into two types based on their proliferative and epithelial state and differential potential to interact with PBMCs. Better understanding of CTC subtypes and their intravascular interactions may help design treatments directed against CTCs with high metastatic and immune‐evasive competence.